It is designed to fit into a daily wellness routine
Timing prevents premature assessment of dissolution completion
Reminder: Retatrutide remains investigational it is in Phase 3 trials (TRIUMPH program) and is not approved for human use as of 2026
Results vary by individual based on goals, lifestyle, and medical conditions
The compound does not appear to have carcinogenic activity in the models tested, and its interaction with tumor biology, a legitimate concern given that angiogenesis also supports tumor vascularization, has been examined in several studies without evidence of tumor promotion at physiological doses
In summary, epithalon has been found to: Increase the lifespan of animal test subjects (mice and fruit flies) Restore the circadian rhythm of melatonin and cortisol production in animal test subjects (rhesus monkeys) Prolong the integrity of the eye retina in animal test subjects (rats) Improve visual functions in elderly patients with age-related difficulties Despite these promising results, formal research into epithalon and anti-aging remains lacking, prompting researchers to actively explore the peptide